DHA sbir phase 1 proposal H243-001-0051, titled "halovax: clay nanotube-based vaccine delivery patches for the sustained release of an HIV vaccine", medical R & D contract.
Ended Purchase Order Awarded Last action
- Contract number
- HT942525P0019
- Awardee
-
Grapheno, LLC UEI YKPQU2RGB1M6
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $249,979
Award facts
- Opportunity
-
- HQ003420RBDST Solicitation number
- Contract value 100% obligated
- $249,978.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- 14 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Forbing, LA 71106, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $249,979 |
About this award
The Defense Health Agency (DHA) awarded a Small Business Innovation Research (SBIR) Phase I contract to Grapheno, LLC for $249,978.59 to develop HaloVax, a clay nanotube-based vaccine delivery system designed to enable sustained release of an HIV vaccine through transdermal patches. This medical research and development contract, designated as a Total Small Business set-aside, represents the DHA's investment in innovative therapeutic delivery mechanisms that could advance HIV prevention capabilities within the Department of Defense and broader public health applications. The contract was awarded on January 27, 2025, with an ultimate completion date of August 26, 2025, establishing a nine-month Phase I research period for feasibility assessment and proof-of-concept development.
Grapheno, LLC, headquartered in Shreveport, Louisiana, will execute the research and development work at its primary location. As a SBIR Phase I award, this contract emphasizes the validation of innovative concepts with commercial potential while supporting small business participation in federal research initiatives. The firm fixed-price purchase order structure provides defined budgetary parameters for the research phase, with potential for Phase II advancement contingent upon Phase I results demonstrating technical merit and commercialization viability.
Quick answers
Who was awarded contract HT942525P0019?
HT942525P0019 was awarded to Grapheno, LLC by Defense Health Agency (Department of Defense) on January 27, 2025.
How much is contract HT942525P0019 worth?
The government has obligated $249,979 on HT942525P0019.
Was contract HT942525P0019 competed?
The government received 14 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award